- Stocks
- Healthcare
- NASDAQ: ABMD

Price (delayed)

$265.25

Market cap

$11.99B

P/E Ratio

57.66

Dividend/share

N/A

EPS

$4.6

Enterprise value

$11.78B

Abiomed is a publicly-traded medical devices company that develops and manufactures the circulatory support device Impella, the world’s smallest heart pump. The company is headquartered in Danvers, Massachusetts and has

ABMD's quick ratio is up by 26% since the previous quarter and by 21% year-on-year

Abiomed's equity has increased by 19% YoY and by 7% from the previous quarter

ABMD's EPS is up by 31% since the previous quarter but it is down by 6% year-on-year

The net income has grown by 31% from the previous quarter but it has contracted by 6% YoY

The company's gross profit fell by 4.5% YoY

ABMD's gross margin is down by 2.4% year-on-year

What are the main financial stats of ABMD

Market
Valuations
Earnings

Shares outstanding

45.19M

Market cap

$11.99B

Enterprise value

$11.78B

Price to earnings (P/E)

57.66

Price to book (P/B)

10.11

Price to sales (P/S)

14.9

EV/EBIT

43.59

EV/EBITDA

40.24

EV/Sales

14.68

Revenue

$802.86M

EBIT

$270.32M

EBITDA

$292.84M

Free cash flow

$246.05M

Per share
Balance sheet
Liquidity

EPS

$4.6

Free cash flow per share

$5.46

Book value per share

$26.25

Revenue per share

$17.8

TBVPS

$27.71

Total assets

$1.33B

Total liabilities

$145.57M

Debt

$0

Equity

$1.18B

Working capital

$611.41M

Debt to equity

0

Current ratio

6.81

Quick ratio

5.84

Net debt/EBITDA

-0.69

Margins
Efficiency
Dividend

EBITDA margin

36.5%

Gross margin

80.8%

Net margin

25.9%

Operating margin

27.9%

Return on assets

16.7%

Return on equity

18.9%

Return on invested capital

30.3%

Return on capital employed

22.1%

Return on sales

33.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Abiomed stock price performed over time

Intraday

-1.1%

1 week

0.54%

1 month

4.08%

1 year

37.99%

YTD

55.49%

QTD

-4.26%

How have Abiomed's revenue and profit performed over time

Revenue

$802.86M

Gross profit

$648.77M

Operating income

$223.71M

Net income

$207.82M

Gross margin

80.8%

Net margin

25.9%

The net income has grown by 31% from the previous quarter but it has contracted by 6% YoY

ABMD's net margin is up by 30% since the previous quarter but it is down by 3.7% year-on-year

The company's operating income fell by 10% YoY

Abiomed's operating margin has decreased by 8% YoY

What is Abiomed's growth rate over time

What is Abiomed stock price valuation

P/E

57.66

P/B

10.11

P/S

14.9

EV/EBIT

43.59

EV/EBITDA

40.24

EV/Sales

14.68

ABMD's EPS is up by 31% since the previous quarter but it is down by 6% year-on-year

ABMD's P/E is 25% below its 5-year quarterly average of 77.3 but 20% above its last 4 quarters average of 48.2

ABMD's P/B is 23% below its 5-year quarterly average of 13.1 but 19% above its last 4 quarters average of 8.5

Abiomed's equity has increased by 19% YoY and by 7% from the previous quarter

The price to sales (P/S) is 30% higher than the last 4 quarters average of 11.5 but 2.6% lower than the 5-year quarterly average of 15.3

The company's revenue fell by 2.1% YoY

How efficient is Abiomed business performance

Abiomed's ROA has increased by 26% from the previous quarter but it has decreased by 19% YoY

ABMD's return on sales is up by 25% since the previous quarter but it is down by 2.6% year-on-year

ABMD's return on equity is up by 25% since the previous quarter but it is down by 19% year-on-year

The ROIC has grown by 22% from the previous quarter but it has contracted by 13% YoY

What is ABMD's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ABMD.

How did Abiomed financials performed over time

ABMD's quick ratio is up by 26% since the previous quarter and by 21% year-on-year

Abiomed's current ratio has increased by 21% from the previous quarter and by 18% YoY

ABMD's debt is 100% smaller than its equity

Abiomed's equity has increased by 19% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.